Celiac Disease Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Zedira, Dr. Falk Pharma, Takeda, ImmunoGenX, Provention Bio, Sanofi, Topas

DelveInsight’s “Celiac Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Celiac Disease, historical and forecasted epidemiology as well as the Celiac Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Celiac Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Celiac Disease Market Forecast

Some of the key facts of the Celiac Disease Market Report: 

• The Celiac Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In July 2022, Due to dismal interim findings, 9 Metres Biopharma terminated their Phase III product larazotide for the treatment of celiac disease.
• In October 2022, Takeda and Zedira and Dr. Falk Pharma reached an agreement to develop ZED1227/TAK-227 for the treatment of celiac disease
• The Celiac Disease Foundation states that celiac disease is a dangerous autoimmune condition that affects one in every 100 persons globally. Additionally, 2.5 million Americans are untreated and at danger of developing long-term health issues
• In 2021, there were 1.4 million cases of Celiac Disease that had been diagnosed as being prevalent worldwide, with 0.7 million of those cases occurring in the United States
• Key Celiac Disease Companies: Zedira, Dr. Falk Pharma, Takeda, ImmunoGenX, Provention Bio, Sanofi, Topas Therapeutics GmbH, Pfizer, 9 Meters Biopharma, Inc., ChemoCentryx, BioLineRx, Ltd., and others
• Key Celiac Disease Therapies: TAK-227/ZED1227, Latiglutenase(IMGX003), Ordesekimab, TAK-101 and Zamaglutenase, TPM502, Ritlecitinib, TAK-062, larazotide acetate, CCX282-B, BL-7010, and others
• The Celiac Disease epidemiology based on gender analyzed that, females are affected more than males
• The Celiac Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Celiac Disease pipeline products will significantly revolutionize the Celiac Disease market dynamics.

Celiac Disease Overview

In contrast to other autoimmune diseases, celiac disease exhibits unusual characteristics, such as the complete repair of mucosal injury as well as the reversibility of its progression and chronic dynamics, with complete avoidance of gluten.

Get a Free sample for the Celiac Disease Market Report:

https://www.delveinsight.com/report-store/celiac-disease-cd-market

Celiac Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Celiac Disease Epidemiology Segmentation:

The Celiac Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Celiac Disease
• Prevalent Cases of Celiac Disease by severity
• Gender-specific Prevalence of Celiac Disease
• Diagnosed Cases of Episodic and Chronic Celiac Disease

Download the report to understand which factors are driving Celiac Disease epidemiology trends @ Celiac Disease Epidemiology Forecast

Celiac Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Celiac Disease market or expected to get launched during the study period. The analysis covers Celiac Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Celiac Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Celiac Disease Therapies and Key Companies

• TAK-227/ZED1227: Zedira, Dr. Falk Pharma, and Takeda
• Latiglutenase(IMGX003): ImmunoGenX
• Ordesekimab: Provention Bio/Sanofi
• TAK-101 and Zamaglutenase: Takeda
• TPM502: Topas Therapeutics GmbH
• Ritlecitinib: Pfizer
• TAK-062: Takeda
• larazotide acetate: 9 Meters Biopharma, Inc.
• CCX282-B: ChemoCentryx
• BL-7010: BioLineRx, Ltd.

Discover more about therapies set to grab major Celiac Disease market share @ Celiac Disease Treatment Market

Celiac Disease Market Strengths

• The pipeline activity of Celiac Disease is quite efficient with the presence of variable key players such as ImmunogenX, Provention Bio, Takeda, etc., which are efficiently involved in developing milestone treatment options.

Celiac Disease Market Opportunities

• Several organizations such as Celiac Disease Foundation, National Celiac Association (NCA), American Celiac Disease Alliance (Celiac Disease A), Coelic UKetc. are actively working to provide information and awareness of the disorder

Scope of the Celiac Disease Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Celiac Disease Companies: Zedira, Dr. Falk Pharma, Takeda, ImmunoGenX, Provention Bio, Sanofi, Topas Therapeutics GmbH, Pfizer, 9 Meters Biopharma, Inc., ChemoCentryx, BioLineRx, Ltd., and others
• Key Celiac Disease Therapies: TAK-227/ZED1227, Latiglutenase(IMGX003), Ordesekimab, TAK-101 and Zamaglutenase, TPM502, Ritlecitinib, TAK-062, larazotide acetate, CCX282-B, BL-7010, and others
• Celiac Disease Therapeutic Assessment: Celiac Disease current marketed and Celiac Disease emerging therapies
• Celiac Disease Market Dynamics: Celiac Disease market drivers and Celiac Disease market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Celiac Disease Unmet Needs, KOL’s views, Analyst’s views, Celiac Disease Market Access and Reimbursement 

To know more about Celiac Disease companies working in the treatment market, visit @ Celiac Disease Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Celiac Disease Market Report Introduction

2. Executive Summary for Celiac Disease

3. SWOT analysis of Celiac Disease

4. Celiac Disease Patient Share (%) Overview at a Glance

5. Celiac Disease Market Overview at a Glance

6. Celiac Disease Disease Background and Overview

7. Celiac Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Celiac Disease 

9. Celiac Disease Current Treatment and Medical Practices

10. Celiac Disease Unmet Needs

11. Celiac Disease Emerging Therapies

12. Celiac Disease Market Outlook

13. Country-Wise Celiac Disease Market Analysis (2019–2032)

14. Celiac Disease Market Access and Reimbursement of Therapies

15. Celiac Disease Market Drivers

16. Celiac Disease Market Barriers

17.  Celiac Disease Appendix

18. Celiac Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/